Misofar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Misofar

Quick Facts

Property Description
Active ingredient Misoprostol
Form Tablet (single-ingredient)
Pharmacological class Prostaglandin Analog, Cytoprotective, Uterotonic
General purpose Gastric protection and uterine activity management
Origin Synthetic (mathrmPGE1 analog)

Misofar: Defining the Prostaglandin Analog

Misofar is the trade name for a pharmaceutical preparation whose active component is Misoprostol. This substance is classified as a Prostaglandin Analog, meaning it is a synthetic compound engineered to chemically mimic the function of the naturally occurring Prostaglandin mathrmE1 (mathrmPGE1) found in the human body. As a single-ingredient product, Misofar is supplied as a tablet. The classification as a Prostaglandin Analog is key to understanding its identity, as this structure dictates its specific effects on the body's cells and tissues.

What Classifies Misofar as Cytoprotective and Uterotonic?

Misofar's general purpose is defined by its ability to act as both a Cytoprotective Agent and a Uterotonic Agent, based on where its mathrmPGE1-mimicking action occurs. Cytoprotective means it helps safeguard the sensitive lining of the stomach by boosting its natural defenses, such as increasing protective mucus and bicarbonate secretion. Uterotonic means it can manage uterine muscle activity by stimulating contractions and promoting the softening of the cervical tissue.

This dual efficacy is clinically recognized for its role in both gastroenterology and obstetrics. At its core, Misofar is a versatile, prescription-only medication used to either protect the gastric mucosa or modulate uterine function, depending entirely on the medical necessity.

Regulatory References

  1. NIH National Library of Medicine

What side effects are possible with Misofar?

Possible Side Effects and Safety Information

The safety profile of Misofar (Misoprostol) is formally documented in government regulatory labeling, with adverse reactions classified by frequency and body system. The most commonly reported effects involve the Gastrointestinal Disorders and the Reproductive System and Breast Disorders.


Official Frequency Classification

Adverse reactions are classified by regulatory agencies:

  • Very Common: Diarrhea and Abdominal pain. These effects are typically most frequent and severe at the start of treatment and are often dose-related.
  • Common: Nausea, Vomiting, Headache, Flatulence, Dyspepsia, and Rash.
  • Uncommon/Rare: Includes Fever, Menstrual disorders, Uterine hemorrhage, Anaphylactic reaction, and serious, rare risks such as Uterine rupture (primarily in obstetric use).

Serious Adverse Reactions and Population Constraints

Official labeling documents serious risks tied to the drug’s properties. Misoprostol is a recognized teratogen; exposure during pregnancy carries a high risk of Fetal death and severe Birth defects. For the gastric ulcer indication, the medication is contraindicated in established pregnancy and requires women of childbearing potential to use effective contraception.

Regulatory documentation also includes explicit safety notes for specific groups, such as advising caution in older adults as gastrointestinal effects may be more pronounced. The overall profile emphasizes the high likelihood of common but manageable gastrointestinal effects against the low-frequency, critically severe risks related to its action on the uterus.

Overdose and Emergency Response

Misofar Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Misofar (Misoprostol) by listing specific systemic and severe complications that mandate immediate action.

Documented Overdose Manifestations

System Official Regulatory Statement
Cardiovascular/CNS Signs may include hypotension, bradycardia, palpitations, sedation, tremor, convulsions, and dyspnea.
Gastrointestinal Overdose presentations include severe abdominal pain and diarrhea; higher doses (e.g., 1600 mu g total daily dose) have been associated with increased discomfort.

Severe Outcomes and Emergency Action

Official labeling recognizes severe, life-threatening complications, particularly the risk of uterine rupture and subsequent hypovolemic shock resulting from prolonged heavy vaginal bleeding.

Urgent medical attention must be sought if complications such as prolonged heavy bleeding, sustained fever, severe abdominal pain, or syncope occur. If an overdose is suspected, treatment is strictly symptomatic and supportive therapy, as regulatory information states that no specific antidote is known, and procedures like hemodialysis are not expected to be useful. Patients with renal impairment may experience increased effects due to slower clearance, which is a factor in managing potential overdose.

Therapeutic Uses of Misofar

What Misofar Treats: Main Uses and Benefits

Supporting the Stomach Lining in High-Risk Patients

Misofar is generally used to provide support for the stomach lining, addressing the symptoms related to physical discomfort and the risk of gastric ulceration that may occur in adults, particularly older adults, requiring continuous, long-term nonsteroidal anti-inflammatory drug (NSAID) therapy. This medication is commonly used to help protect the stomach lining in these specific cases. The therapeutic benefit contributes to easing the overall symptom load associated with potential irritation, which supports patients during periods of heightened discomfort while they continue necessary chronic pain treatment.


Managing Uterine Function in Obstetric Scenarios

This medication is applied across therapeutic domains that involve modulation of uterine muscle activity or cervical tissue softening. The key benefits include supporting the non-surgical management of early pregnancy loss or abortion and is commonly used to help with addressing acute severe bleeding in a postpartum setting. It may assist with achieving the necessary cervical ripening prior to certain medical procedures or labor induction, providing supportive relief when symptoms interfere with routine activities.


Quick Fact Block

Property Description
Quick Fact: Relief for... Symptoms related to gastric irritation and the need for uterine activity modulation.
Conditions Used: NSAID-induced ulcers (prevention), early pregnancy loss, postpartum hemorrhage.
Patient Benefit: Contributes to improved comfort during periods of heightened symptoms with chronic NSAID use; assists with clinical management during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Misofar

Misofar (misoprostol) is a medicine with distinct eligibility rules that vary significantly based on the intended use. Factual eligibility information is derived strictly from regulatory documents for the drug's various formulations and indications.


Contraindicated Populations (Must Not Use)

Use of misoprostol is contraindicated in multiple scenarios, most notably in:

  • Pregnancy (when used for ulcer prevention), due to the risk of birth defects, abortion, or uterine rupture.
  • History of Cesarean section or major uterine surgery (when used for labor induction or other uterotonic purposes).
  • Allergy to misoprostol or other prostaglandins.
  • Situations where oxytocic drugs are contraindicated (e.g., cephalopelvic disproportion, active genital herpes, placenta previa, or fetal distress).
  • Multiparous women with six or more previous term pregnancies (for labor induction).

Restricted or Special Consideration Groups

  • Women of childbearing potential (for ulcer prevention): Must have a negative pregnancy test within two weeks before starting therapy and use effective contraception throughout treatment. Therapy must begin on the second or third day of the next normal menstrual cycle.
  • Pediatric patients (under 18): Safety and efficacy have not been established for the obstetrical indication.
  • Elderly patients (over 64) and those with renal impairment: Dosage adjustment is not routinely recommended but may be necessary if the usual dose is not tolerated, due to increased systemic exposure.

Pregnancy and Lactation Status

Misoprostol is contraindicated in pregnancy when used for the ulcer prevention indication. When used for labor induction at term, it is permitted. Misoprostol acid is excreted in breast milk at extremely low levels, and no special precautions are generally required.


Connection to the overall eligibility profile

Regulatory documents strictly define eligibility based on the drug's strong uterotonic effects. This requires a complete prohibition on its use for ulcer prevention in pregnant women and imposes strict controls (pregnancy testing, contraception) on women of childbearing potential. In the obstetric setting, use is only permitted under specific, high-monitoring conditions, and it is explicitly contraindicated in patients with risk factors for uterine hyperstimulation or rupture, such as prior Cesarean delivery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Misofar (Misoprostol) focuses on pharmacodynamic reinforcement and specific pharmacokinetic alterations, with a documented absence of interaction through major metabolic pathways.

Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Official Interaction Statement
Uterotonic Agents (e.g., Oxytocin) Co-administration is documented to result in additive uterotonic effects, increasing the potential for uterine hyperstimulation.
Magnesium-Containing Antacids Concurrent use is associated with pharmacodynamic reinforcement on the digestive tract, which elevates the risk and potential severity of diarrhea.
High-Fat Meal Ingestion with a high-fat meal reduces the maximum plasma concentration (Cmathrmmax) of the active metabolite, which alters the rate and extent of systemic exposure.

Metabolic Pathway and Population Notes

Regulatory data specifies that Misofar’s metabolism occurs via fatty acid oxidising systems and does not involve the Cytochrome P450 (CYP450) enzyme system, confirming a low potential for metabolic drug–drug interactions via this pathway. In individuals with renal impairment, pharmacokinetic studies demonstrate an approximate doubling of the T1/2, Cmathrmmax, and AUC of the active metabolite, which represents a labeled population-specific constraint based on altered clearance.

Mechanism of Action

Misofar is a synthetic compound classified as a Prostaglandin E1 analog. Its primary mechanism is agonism; it initiates action by binding to and activating specific Prostaglandin E receptors (primarily EP2, EP3, and EP4) located on target cells, thereby modulating the PGE1-regulated signaling pathway.

This molecular interaction drives distinct physiological changes across two main systems. In the stomach lining, receptor activation simultaneously reduces the output of gastric acid and enhances the production of mucosal factors (mucus and bicarbonate). This regulation of local secretory processes alters the physiological state of the gastric mucosa.

In smooth muscle tissues, particularly the uterus, receptor binding leads to increased intracellular calcium concentrations. This cascade triggers and sustains muscle contractions (increased tone and motility). Concurrently, the mechanism promotes the structural breakdown of collagen in associated connective tissues, contributing to changes in tissue consistency.

Dosage and Administration Information

How to Use Misofar

Misofar (Misoprostol) administration is defined by two distinct administration pathways, which establish separate dosage forms, frequencies, and usage conditions. These protocols are based on whether the goal is gastric protection or uterine activity modulation.

Administration Protocols

Feature Gastric Protection (Ulcer Prophylaxis) Uterine Activity Management (Specific Protocols)
Route of Administration The tablet is administered orally (e.g., swallowed whole). Administration involves non-oral routes, such as vaginal, sublingual, buccal, or rectal, depending on the indication.
Labeled Dosing The typical dose is 200 mu g per dose, taken four times daily (QID). A lower dose of 100 mu g QID may be used if the higher dose is poorly tolerated. Doses are highly variable, often ranging from 400 mu g to 800 mu g for single or initial doses, followed by repeated administration at intervals specific to the protocol.
Frequency & Duration Sustained daily dosing (QID), continued for the entire duration of the non-steroidal anti-inflammatory drug (NSAID) therapy. Short-term use or restricted to a specific time interval and number of doses as defined by the acute medical protocol.

Administration Specifics

For gastric protection, the tablets are directed to be taken with food to maximize tolerability, with the final daily dose administered at bedtime. In cases of renal impairment, the standard adult dose may be used, though a reduction may be considered if the dose is not tolerated. For all applications involving uterine activity management, administration is often restricted to a medically supervised setting. If a dose is missed during the long-term ulcer prophylaxis regimen, the missed dose should be skipped and the next dose resumed at the regularly scheduled time; the dose should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Misofar


Evidence for use in Ulcer Treatment and Healing

Studies have examined Misofar for use in managing ulcers, a condition marked by functional limitations and outcomes related to physical discomfort. Research explored its role in the healing process and its application in settings where ulcers are already present, typically focusing on outcomes linked to inflammatory or irritative states.

The findings describe patterns observed in the studies regarding how ulcer healing was evaluated in the study populations. For instance, some research explored short-term symptom changes related to the healing process when Misofar was evaluated in study groups compared to control groups. However, the available evidence may not be fully consistent across all study designs, and the quality of the evidence varies across studies.


Evidence for use in Preventing Ulcers

Misofar was studied for its potential role in preventing the development of ulcers, especially in people who are taking certain other medications. This research examined outcomes capturing phases of heightened symptom activity and was conducted in observational settings evaluating daily-life functioning for individuals at risk.


Evidence for use in Inducing Labor

Research has explored Misofar's use in a hospital setting for the induction of labor. These studies was evaluated in specific clinical contexts to understand the patterns observed in the studies related to the process of labor. The studies monitored outcomes related to systemic or functional imbalance and the progression of labor, often in clinical trials assessing short-term or episodic symptom patterns.


Long-term Studies and Follow-up

This section summarizes what is currently known about using Misofar for defined time intervals longer than short-term use. Research was observed in some studies to determine the patterns observed in the studies over the longer term and what was observed in terms of sustained changes across different populations. However, data on long-term outcomes remain insufficient and are still emerging.


What is Still Uncertain About Misofar

One key area is the lack of head-to-head research, meaning comparative evidence is lacking for some of its uses. Furthermore, while many studies use patient-reported outcomes describing perceived discomfort, in some research, the consistency of these findings appears to be mixed, or findings were mixed. Understanding the full range of both short-term and long-term patterns and closing these evidence gaps is an ongoing research priority.

Frequently Asked Questions (FAQ)

Common questions about Misofar (FAQ)


Q: What official warnings or boxed statements exist for Misofar?

Misofar carries an IMPORTANT WARNING (often referred to as a Boxed Warning in regulatory documents) regarding the risk of serious complications. This warning is due to the potential for birth defects, abortion, premature birth, and uterine rupture when the drug is administered to pregnant women. This information is highlighted in the official prescribing information.


Q: How long does it usually take to feel the effects of Misofar?

The time it takes to feel the effects can vary widely based on the reason for use and the method of administration. According to regulatory documents, when used for specific protocols (such as in combination with other medicines for termination), the effects, like cramping and bleeding, can begin one to four hours after the drug is administered.


Q: Does Misofar cause tiredness or drowsiness?

Official adverse reaction data indicates that side effects like tiredness, weakness, and fatigue have been reported. Drowsiness has also been reported as a potential effect, though the exact frequency of this specific symptom is not precisely known. The potential for these effects means they may affect a person’s alertness.


Q: Does using Misofar require regular blood tests or monitoring?

Follow-up assessments are specifically required for certain uses of the drug, such as in the medical termination regimen. In addition to these required check-ups, official patient information indicates that healthcare providers may check blood work and other lab tests as part of the management of the patient's condition.


Q: Is there a generic version of Misofar available?

Yes, the active ingredient in Misofar, misoprostol, is available as a generic medication. Regulatory agencies approve generic versions after confirming they have the same quality, strength, dosage form, and performance characteristics as the brand-name drug.


Q: Is Misofar affected by common vitamins or supplements?

Official regulatory guidance includes a requirement to inform the doctor about all supplements, herbs, and vitamins being taken. This information supports the healthcare provider's assessment of the complete treatment profile, as no specific common vitamins are listed as interacting in official documents.


Q: Can Misofar cause changes in appetite or weight?

Weight changes have been reported as a possible side effect in the official adverse reaction data for the drug. However, the exact incidence, or how often this occurs in patients, is not precisely known.


Q: If I stop taking Misofar, will the original condition immediately return?

For the purpose of ulcer prevention, official instructions state that the medicine should be taken for the entire duration of the NSAID therapy (the non-steroidal anti-inflammatory drug causing the risk). This requirement indicates that sustained use is necessary to maintain the protective effect against ulcers.


Q: Are there any specific activities or machinery I should avoid when first starting Misofar?

Official patient information notes that the drug may cause effects like drowsiness or fatigue. This information carries a warning to avoid activities requiring high alertness, such as driving or operating machinery, until the individual knows how the drug affects them.


Q: How long has Misofar been available?

The active ingredient in Misofar, misoprostol, was first approved by the U.S. Food and Drug Administration (FDA) on December 27, 1988, under the brand name Cytotec.


Q: Can Misofar be taken with alcohol?

Official information indicates that alcohol consumption is a known risk factor that increases the likelihood of developing stomach ulcers. Because this increase would counteract the drug's protective effect, use with alcohol is not advised by healthcare professionals.


Q: What happens if a user accidentally takes too much Misofar?

In case of an accidental overdose, official guidance notes that the procedure is to immediately contact a Poison Control center or emergency medical services.


Q: Is Misofar the same kind of medicine as [similar drug name]?

Misofar's active ingredient, misoprostol, is classified as a Prostaglandin E1 analog, meaning it mimics a natural substance in the body. Studies and official prescribing information indicate that it does not have a clinically significant effect on the drug levels of non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac or ibuprofen.


Q: What common over-the-counter drugs might interfere with Misofar?

Known drug interactions listed in official documents include certain antacids, particularly those that contain magnesium, as concurrent use can increase the risk of diarrhea. The official label also notes that Misofar does not significantly affect the drug levels of common pain relievers like aspirin, diclofenac, or ibuprofen.


Q: Is Misofar considered safe for people over 65?

Official prescribing information includes caution for use in older adults, particularly those with pre-existing heart or blood vessel issues. Dosage adjustments are not routinely recommended but may be considered if the usual dose is not tolerated.


Q: Are there any major diet changes required when taking Misofar?

The drug is often taken with meals for better tolerability. Official information also notes that taking the drug with a high-fat meal can alter the rate at which the body absorbs it. Outside of these specific considerations, there are no other reports of food interactions noted in the regulatory documents.


Q: Can Misofar be taken at any time of day?

The required timing of the drug depends on its specific use. For the purpose of ulcer prevention, the medication is typically taken four times a day (QID), and the administration protocol specifies the final dose of the day is taken at bedtime.


Q: Are the side effects of Misofar generally mild?

The most common side effects, such as gastrointestinal upset, are often reported as transient. However, official product information indicates the drug carries an IMPORTANT WARNING for serious events. These rare but severe risks include birth defects and uterine rupture.


Q: What is the typical duration someone stays on Misofar treatment?

The duration of treatment is determined by the specific medical indication. For ulcer prevention, official regulatory instructions define the treatment duration as the duration of the non-steroidal anti-inflammatory drug (NSAID) therapy that necessitated the protective treatment.


Q: Is Misofar approved by the FDA for all its described uses?

The FDA has approved the drug to prevent NSAID-induced ulcers and, in a specific regimen with another drug, for the medical termination of intrauterine pregnancy (up to 70 days gestation). These are the specific, officially approved indications.


Q: Is Misofar known to cause any long-term health issues?

Official prescribing information includes data from long-term studies. For instance, animal studies showed no evidence of an effect on tumor incidence. Additionally, human studies tracking patients for up to one year showed no long-term increase in surface gastric cells.


Q: Is it true that Misofar is only for severe cases?

No, that is not accurate. The drug is officially indicated for ulcer prophylaxis (prevention), which is not considered a severe case. It is also used in specific conditions like labor induction and postpartum hemorrhage management under controlled medical settings.


Q: Does Misofar interact with grapefruit or grapefruit juice?

Official patient information includes a recommendation that individuals who frequently consume grapefruit or drink grapefruit juice discuss this with their healthcare provider.


Q: Does Misofar affect mental clarity or focus?

Official patient information includes a warning that avoiding tasks requiring alertness, such as driving or operating heavy machinery, is recommended until the individual knows how the drug affects their mental clarity.

How should Misofar be stored and disposed of?

How to Store and Dispose of Misofar

Misofar (misoprostol) tablets must be stored according to specific environmental and temperature constraints to maintain their stability, as defined in official regulatory labeling.

Storage Requirements

Condition Regulatory Specification
Temperature Store at or below 25°C (77°F).
Protection Keep in a dry area, away from excess heat and protected from light. Do not freeze.
Packaging Keep the medication in the container it came in, tightly closed and out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Misofar, do not throw the product into household waste or wastewater. The medication must be returned to an authorized pharmacy or collection point for proper pharmaceutical waste handling to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Misofar found in:

A-Z Index: